Announcements Trials
Browse Landscape

Status

Completed 72Terminated 16Unknown 4Withdrawn 3Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Afatinib 3niraparib 2lenvatinib 2ibrutinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Gefitinib 2Capecitabine 2Abiraterone Acetate 23-Iodobenzylguanidine 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1pomalidomide 1pirtobrutinib 1pertuzumab 1olaratumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × INDUSTRY × Lapatinib × Clear all
NCT00338247 2016-04-06

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Novartis

Approved for marketing
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡